Document:

EX-10.13

 Exhibit. 10.13 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 
  

					
	

	 		  	 Oncimmune (USA) LLC
 8960 Commerce Drive,
Building 6
 De Soto, KS 66018, USA
  

Tel +1 913 583 9000
 Fax +1 913 583 9001

 August 22, 2019 
 De Soto
Investments, L.L.C. 
 8997 Commerce Drive 
 De Soto, KS 66018

  

	 	Re:	 Commercial and Industrial Lease Agreement (the “Lease”), between Fish Development, LLC and
Oncimmune (USA) LLC (“Oncimmune”), dated November 29, 2007, as amended and as assigned to De Soto Investments, L.L.G (“Landlord”) over premises situated at 8960 Commerce Drive, Building 6, De Soto Kansas, 66018, USA

 Dear Ladies and Gentlemen: 
 As
you may be aware, an affiliate of Oncimmune has entered into an asset purchase agreement to sell substantially all of Oncimmune’s assets as a going concern to Biodesix, Inc. (“Biodesix”), dated June 27, 2019 (the
“Sale”). Oncimmune intends to assign its rights and obligations under the Lease to Biodesix in connection with the Sale. Pursuant to the terms of Paragraph 9 the Lease, Oncimmune hereby notifies Landlord of its intention to assign
the Lease to Biodesix as of and subject to the consummation of the Sale. Also pursuant to Paragraph 9 of the Lease, by its signature hereto Biodesix acknowledges and agrees that it will assume all obligations of Oncimmune as “Tenant” under
the Lease. 
 To ensure no interruption of the continued contractual relationship under the Lease, Oncimmune requests that you countersign this letter in
the space provided below to indicate (i) your receipt of this notice of the Sale and your acknowledgement that this notice complies with the requirements of the Lease, including, without limitation, those under Paragraph 9 of the Lease, and
(ii) your acknowledgment and consent, to the extent required under the Lease, that the Sale and associated assignment of the Lease to Biodesix shall not constitute a violation, breach or default under any provision of the Lease or result in any
rights of acceleration or payment of any kind. 
 Subject to the satisfaction of customary closing conditions, we expect to consummate the Sale on or about
November 1, 2019. 
 Please return a countersigned copy of this letter by email to [***]. Your prompt response would be greatly appreciated. 

 [Remainder of Page Intentionally Left Blank] 

  
 [Signature Page to
Notice Letter] 

 
	
	Very truly yours,
	
	ONCIMMUNE (USA) LLC
	
	/s/ Marco G. Casarin
	 Marco G. Casarin
 General Manager

  

			
	ACKNOWLEDGED AND AGREED TO:
	
	BIODESIX, INC.
		
	By:	 	/s/ Robin Harper Cowie
		
	Name:	 	Robin Harper Cowie
		
	Title:	 	Chief Financial Officer
		
	Date:	 	            
	
	ACKNOWLEDGED AND AGREED TO:
	
	DE SOTO INVESTMENTS, LLC
		
	By:	 	/s/ Farrellynn A. Wolf
		
	Name:	 	Farrellynn A. Wolf
		
	Title:	 	CFO
		
	Date:	 	9/9/19

  
 [Signature Page to
Notice Letter]EX-10.14.2

 Exhibit 10.14.2 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 
 LIMITED CONSENT AGREEMENT 

AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT 

This LIMITED CONSENT AGREEMENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Consent”) is made
as of this 30th day of June, 2018, by and among BIODESIX, INC., a Delaware corporation (“Borrower”) and INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership in its capacity as Collateral Agent
(“Collateral Agent”) for the Lenders and as a Lender (in such capacity, the “Required Lenders”). 

RECITALS 

A.    Collateral Agent, Lenders, and Borrower have entered into that certain Loan and Security Agreement,
dated as of February 23, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which the Lenders have agreed to make certain advances of money and to extend certain
financial accommodations to Borrower and certain of its Affiliates in the amounts and manner set forth in the Loan Agreement. 

B.    Borrower desires to enter into that certain Asset Purchase Agreement and Plan of Reorganization,
dated as of June 30, 2018 (in form and content reasonably acceptable to Collateral Agent and the Lenders, the “Asset Purchase Agreement”), by and between Borrower and Integrated Diagnostics, Inc., a Delaware corporation
(“Seller”) pursuant to which Borrower intends to acquire substantially all of the assets of Seller in exchange for the issuance by Borrower of shares of its Series G Preferred Stock. 

C.    The transactions contemplated by the Asset Purchase Agreement are prohibited under the Loan
Agreement. 
 D.    Borrower has requested that Collateral Agent and the Required Lenders consent
(subject to the terms and conditions set forth herein) to the execution of the Asset Purchase Agreement attached hereto as Exhibit A, and the consummation of the transactions described therein. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Consent, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Collateral Agent, the Required Lenders and Borrower hereby agree as follows: 

1.    Recitals; Construction. This Consent shall constitute a Loan Document and the Recitals
and each reference to the Loan Agreement, unless otherwise expressly noted, will be deemed to reference the Loan Agreement as modified hereby. The Recitals set forth above shall be construed as part of this Consent as if set forth fully in the body
of this Consent. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Loan Agreement (including those capitalized terms used in the Recitals hereto). 

2.    Limited Consent. Subject to the terms and conditions set forth herein, Collateral Agent
and the Required Lenders hereby consent to the execution of the Asset Purchase Agreement and the performance by Borrower of its obligations thereunder in accordance with the terms thereof and the consummation of the transactions described therein
and agrees that in each case, that the execution and, as applicable, the performance of the Borrower’s obligations under and in accordance with the terms of such 

  
 1 

 
agreements shall not, in and of itself, constitute an “Event of Default” under the Loan Agreement. The consent set forth in this Section 2 and the amendments
set forth in Section 3 below, are effective solely for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (i) be a consent to any other amendment, waiver or modification
of any other term or condition of the Loan Agreement or of any other Loan Document; (ii) prejudice any right that Collateral Agent or Lenders have or may have in the future under or in connection with the Loan Agreement or any other Loan
Document; (iii) constitute a consent to or waiver of any past, present or future Default or Event of Default or other violation of any provisions of the Loan Agreement or any other Loan Documents, (iv) create any obligation to forbear from
taking any enforcement action, or to make any further extensions of credit or (vi) establish a custom or course of dealing among any of the Borrower, on the one hand, and Collateral Agent or any Lender, on the other hand. 

3.    Amendments to Loan Agreement. The Loan Agreement hereby is amended as follows: 

(a)    The following defined term hereby is added to Section 13 of the Loan Agreement to read as
follows: 
 “Second Amendment Effective Date” means June 30, 2018. 

(b)    Section 6.12 of the Loan Agreement hereby is amended and restated in its entirety to read as
follows: 
 “6.12    New Equity. Borrower shall receive net proceeds from the issue
and sale of Borrower’s equity securities (or convertible Subordinated Debt, provided there is no cash payments of principal or interest (or otherwise) thereon during the term of this Agreement), from and after the Effective Date (but excluding
the proceeds of any such sale to Collateral Agent (or any Affiliate of Collateral Agent) on or about the Effective Date) of at least [***], or such lesser amount as may be approved by Borrower’s board of directors, based upon revised financial
projections reviewed and approved by Borrower’s board of directors, and subject to Collateral Agent’s prior written consent; provided that (i) not less than [***] of such proceeds shall be received by Borrower no later than
December 31, 2018; (ii) not less than [***] of such proceeds shall be received by Borrower no later than March 31, 2019; and (iii) not less than the remaining [***] of such proceeds received by Borrower no later than
September 30, 2019.” 
 (c)    Annex X to the Loan Agreement hereby is replaced in its entirety
with Annex X attached hereto; provided that column 2 and, as a result of any such changes, column 3, of such Annex X may be revised no later than March 31, 2019 based upon the revenue plan as approved by Borrower’s board of directors in
the first quarter of 2019, as such revenue plan may be approved by Collateral Agent in its reasonable discretion. 

4.    Representations and Warranties; Reaffirmation of Security Interest. Borrower hereby
confirms that all of the representations and warranties set forth in the Loan Agreement are true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) with respect to
Borrower as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. Nothing
herein is intended to impair or limit the validity, priority or extent of Collateral Agent’s security interests in and Liens on the Collateral. Borrower acknowledges and agrees that the Loan Agreement, the other Loan Documents and this Consent
constitute the legal, valid and binding obligation of Borrower, and are enforceable against Borrower in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the
enforcement of creditors’ rights generally and by general equitable principles. 

5.    Conditions to Effectiveness. This Consent shall become effective as of the date on
which each of the following conditions has been satisfied, as determined by Agent in its sole discretion: 

  
 2 

 (a)    Borrower shall have delivered to Collateral Agent
this Consent, duly executed by an authorized officer of Borrower; 
 (b)    all representations and
warranties of Borrower contained herein shall be true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) as of the date hereof except to the extent that any such
representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct in all material respects as of such earlier date (and such parties’ delivery of their respective signatures hereto
shall be deemed to be its certification thereof); 
 (c)    prior to and after giving effect to the
agreements set forth herein, no Default or Event of Default shall exist under any of the Loan Documents or shall exist after giving effect to the transactions contemplated by the Asset Purchase Agreement; 

(d)    Collateral Agent shall have received copies of the fully executed and delivered Asset Purchase
Agreement in form and substance reasonably satisfactory to Collateral Agent; 
 (e)    Collateral Agent
shall have received a duly executed Subordination Agreement from each holder of Subordinated Debt, including with respect to the Sellers under (and as defined in) the Asset Purchase Agreement; 

(f)    Collateral Agent shall have received all Lender Expenses incurred to date, which may be debited from
any of Borrower’s accounts; and 
 (g)    Borrower shall have delivered such other documents,
information, certificates, records, permits, and filings as Collateral Agent may reasonably request. 

6.    No Waiver or Novation. The execution, delivery and effectiveness of this Consent shall
not, except as expressly provided in this Consent, operate as a waiver of any right, power or remedy of Collateral Agent, nor constitute a waiver of any provision of the Loan Agreement, the Loan Documents or any other documents, instruments and
agreements executed or delivered in connection with any of the foregoing. Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Loan Agreement or other Loan Documents or any of
Collateral Agent’s rights and remedies in respect of such Defaults or Events of Default. This Consent (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Loan
Agreement. 
 7.    Affirmation. Borrower hereby acknowledges and agrees that the Loan
Agreement and all other Loan Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrower. Borrower covenants and agrees to comply
with all of the terms, covenants and conditions of the Loan Agreement and the Loan Documents, notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent’s or any Lender’s part which might
otherwise constitute or be construed as a waiver of or amendment to such terms, covenants and conditions. 

8.    Miscellaneous. 

(a)    Reference to the Effect on the Loan Agreement. Upon the effectiveness of this Consent,
each reference in the Loan Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of similar import shall mean and be a reference to the Loan Agreement, as modified by this Consent. Except as
specifically set forth above, the Loan Agreement, and all other Loan Documents (and all covenants, terms, conditions and agreements therein), shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrower.

 (b)    THIS CONSENT AND THE RIGHTS, REMEDIES AND OBLIGATIONS OF THE PARTIES HERETO AND HERETO, AND ANY
CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS CONSENT, THE RELATIONSHIP OF THE PARTIES, 

  
 3 

 
AND/OR THE INTERPRETATION AND ENFORCEMENT OF THE RIGHTS AND DUTIES OF THE PARTIES AND ALL OTHER MATTERS RELATING HERETO, HERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR
OTHERWISE), SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, WITHOUT REFERENCE TO ITS CONFLICT OF LAW PROVISIONS. NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND LENDERS SHALL HAVE THE
RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH COLLATERAL AGENT AND LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 11.2(b) OF THE LOAN AGREEMENT) DEEM NECESSARY OR
APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE COLLATERAL AGENT’S AND LENDERS’ RIGHTS AGAINST BORROWER OR ITS PROPERTY. BORROWER EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO THE JURISDICTION OF THE FEDERAL AND STATE
COURTS LOCATED IN THE STATE OF NEW YORK AND ANY SUCH OTHER JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND BORROWER HEREBY WAIVES ANY OBJECTION THAT IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE, OR FORUM
NON CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT. BORROWER HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINTS, AND OTHER PROCESS ISSUED IN SUCH ACTION OR SUIT AND
AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS, AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO BORROWER AT THE ADDRESS SET FORTH IN SECTION 10 OF THE LOAN AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON
THE EARLIER TO OCCUR OF BORROWER’S ACTUAL RECEIPT THEREOF OR [***] BUSINESS DAYS AFTER DEPOSIT IN THE U.S. MAIL, PROPER POSTAGE PREPAID. 

(c)    Incorporation of Loan Agreement Provisions. The provisions contained in
Section 12.2 (Indemnification) and Section 11.1 (Waiver of Jury Trial) of the Loan Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety. 

(d)    Headings. Section headings in this Consent are included for convenience of reference only and
shall not constitute a part of this Consent for any other purpose. 
 (e)    Counterparts. This
Consent may be signed in any number of counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same instrument. Delivery of an executed counterpart of this Consent by facsimile or by
electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed signature page shall be effective as delivery of an original executed counterpart hereof and shall bind the parties hereto. 

(f)    Entire Agreement. This Consent constitutes the entire agreement and understanding among the
parties hereto and supersedes any and all prior agreements and understandings, oral or written, relating to the subject matter hereof. 

(g)    Severability. In case any provision of or obligation under this Consent shall be invalid,
illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired
thereby. 
 (h)    Successors/Assigns. This Consent shall bind, and the rights hereunder shall
inure to, the respective successors and assigns of the parties hereto, subject to the provisions of the Loan Agreement and the other Loan Documents. 

[SIGNATURES APPEAR ON FOLLOWING PAGES] 

  
 4 

 IN WITNESS WHEREOF, intending to be legally bound, and intending that this document
constitute an agreement executed under seal, the undersigned have executed this Consent under seal as of the day and year first hereinabove set forth. 
  

			
	BORROWER
	
	BIODESIX, INC.

 
			
		
	By:	 	 /s/ David Brunel

			
	Name:	 	 David Brunel

 
			
	Title:	 	 CEO

 
			
	
	COLLATERAL AGENT AND LENDER
	
	 INNOVATUS LIFE SCIENCES

LENDING FUND I, LP

 
			
		
	By:	 	Innovatus Life Sciences GP, LP
	Its:	 	General Partner

 
			
		
	By:	 	 /s/ Andrew W. Hobson

			
	Name:	 	 Andrew W. Hobson

			
	Title:	 	 Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]